Opendata, web and dolomites

MMEM SIGNED

Miniaturized Matrixed Enthalpy Metter - Portable, affordable, easy to operate, diagnostic device enabling a rapid & accurate diagnosis of a patient infected by antibiotic-resistant bacteria

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MMEM project word cloud

Explore the words cloud of the MMEM project. It provides you a very rough idea of what is the project "MMEM" about.

resistance    hybridization    cre    tool    doctor    facilities    labs    patient    onto    release    energy    penetration    ip    successful    accurate    2020    locations    capability    complementary    gradually    patients    signal    sales    isolate    first    molecular    immediately    detects    detectable    form    ready    mmem    expansion    pilot    company    utilizes    clinical    diagnosis    genosmart    israel    suspected    made    distributors    fulfills    occurs    agreements    released    resistant    displayed    internal    dependency    start    market    rate    electric    kinds    diagnostic    rooms    bacteria    device    heat    pathogenic    techniques    offices    completion    molecules    sensor    matrixed    operator    solid    pyroelectric    carbapenem    launch    validation    electronic    rapid    antibiotics    bio    reaching    entails    commercial    immobilized    biologic    complicated    decision    strategic    meter    enthalpy    detection    ultimate    dna    point    15    antibiotic    emergency    contrast    care    miniaturized    transduces    plans    laboratories   

Project "MMEM" data sheet

The following table provides information about the project.

Coordinator
GENOSMART LTD 

Organization address
address: 10, JULIELMO MARCONI STREET
city: HAIFA
postcode: 3295524
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙308˙056 €
 EC max contribution 2˙315˙639 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOSMART LTD IL (HAIFA) coordinator 2˙315˙639.00

Map

 Project objective

Miniaturized Matrixed Enthalpy-Meter (MMEM) - a diagnostic device for a rapid and accurate diagnosis of antibiotic resistant bacteria to be used in emergency rooms, clinical laboratories, doctor offices, and other point-of-care locations. GenoSmart, is developing a novel bio-electronic molecular detection system for detection the presence of a pathogenic DNA is a biologic sample obtained from a patient. In particularly the system allows immediate detection of Carbapenem-resistant bacteria which have developed a resistance to all kinds of known antibiotics. The technology is based on a pyroelectric sensor onto a suspected DNA sample is immobilized. The system utilizes heat release during hybridization of complementary DNA molecules. If a successful hybridization between the sensor and the suspected sample molecules occurs, enthalpy (the internal energy) is released in the form of a detectable heat. The sensor immediately detects this released heat and transduces it to an electric signal. Following this detection, the result is displayed to the operator, and a decision if to isolate the patient from other patients is made. In contrast to currently available molecular detection techniques, GenoSmart MMEM device fulfills the essential need for a rapid and accurate diagnosis tool, along with a cost-effective test and without any dependency on labs and complicated facilities.The ultimate objective is to make GenoSmart's MMEM ready for market launch in Europe. This entails a number of technical and strategic objectives, including the completion of the product’s CRE detection capability, the clinical validation through a European clinical study, and the exploitation of its results (IP expansion, commercial agreements with distributors etc.). The Company plans to start sales in 2020, first in Israel as a pilot market, and gradually reaching solid penetration rate 15% of the CRE diagnosis market within 7 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MMEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MMEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

Plasmanorg (2019)

Environmental-friendly organic chemical synthesis in plasma reactor

Read More